JUAN
PASQUAU LIAÑO
Forscher in der Zeit 2022-2023
![Foto de JUAN](/img/nophoto.png)
![Foto de Hospital Universitario Virgen del Rocío](/img/noimage_org.png)
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario Virgen del Rocío (21)
2024
2023
-
EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci
International Journal of Antimicrobial Agents, Vol. 62, Núm. 3
2020
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1
2019
-
DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients
Medicine (United States), Vol. 98, Núm. 32
2018
2016
2014
-
Causas que justifican el cambio del tratamiento antirretroviral en personas con infección por el VIH en España (años 2010-2011). Estudio SWITCH AUDIT
Revista Espanola de Quimioterapia, Vol. 27, Núm. 2, pp. 93-97
2012
-
Programas de optimización de uso de antimicrobianos (PROA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 30, Núm. 1
-
Programas de optimización de uso de antimicrobianos (PROA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH
Farmacia Hospitalaria, Vol. 36, Núm. 1
2011
-
Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100mg once daily in HIV/Hepatitis C Virus-Coinfected Patients
AIDS Patient Care and STDs, Vol. 25, Núm. 7, pp. 395-402
-
Programs to optimize antimicrobial use (PROA) in Spanish hospitals: GEIH-SEIMC, SEFH and SEMPSPH consensus document
Medicina Preventiva, Vol. 17, Núm. 3, pp. 29-39
2010
2009
-
Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: Effect of hepatitis virus co-infection and pre-existing fibrosis
Journal of Antimicrobial Chemotherapy, Vol. 63, Núm. 1, pp. 178-183
2008
-
Liver toxicity of antiretroviral combinations including atazanavir/ ritonavir in patients co-infected with HIV and hepatitis viruses: Impact of pre-existing liver fibrosis
Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 4, pp. 925-932
-
Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens
HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313
2007
-
Ensayo clínico aleatorizado para evaluar tres pautas cortas de tratamiento de la infección latente tuberculosa en pacientes infectados por el VIH
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 25, Núm. 5, pp. 305-310
2005
-
Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naïve patients: The VESD study
HIV Clinical Trials, Vol. 6, Núm. 6, pp. 320-328
2000
-
Prevalence of primary mutations in human immunodeficiency virus with resistance to nucleoside analogues in naive human immunodeficiency virus-infected patients from Andalucía (Spain)
Medicina Clinica, Vol. 115, Núm. 11, pp. 423-425
1999
-
Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B
AIDS, Vol. 13, Núm. 9, pp. 1063-1069
1998
-
Comparative study of bacteremias caused by Enterococcus spp. with and without High-level resistance to gentamicin
Journal of Clinical Microbiology, Vol. 36, Núm. 2, pp. 520-525